TABLE 5.
Summary of sustained virological response in arms treated with pegylated interferon-alpha (PEG IFN-α) + ribavirin (RBV) in HIV-hepatitis C virus (HCV) coinfected patients compared with HCV monoinfected patients
| Study (reference) | Treatment population | n | RBV dose (mg) | PEG IFN | Length of treatment (weeks) | Genotype 1 response (%) | Genotype 2 + 3 response (%) |
|---|---|---|---|---|---|---|---|
| CLINIVIC, Lagunoet al (60)† | Coinfected | 52 | 800/1200 | α-2b | 48 | 38* | 53 |
| RIBAVIC- ANRS(61) | Coinfected | 412 | 800 | α-2b | 48 | 17 | 44 |
| APRICOT (54) | Coinfected | 289 | 800 | α-2a | 48 | 29 | 62 |
| ACTGA5071 (62) | Coinfected | 67 | 600/1000 | α-2a | 48 | 14 | 73 |
| Hadziyannis et al (63) | Monoinfected | 361 | 800 | α-2a | 48 | 41 | 79 |
| Monoinfected | 436 | 1000/1200 | α-2a | 48 | 52 | 80 | |
| Friedet al (87) | Monoinfected | 1121 | 1000/1200 | α-2a | 48 | 46 | 76 |
| Manns et al (88) | Monoinfected | 1530 | 1000/1200 | α-2b | 48 | 42 | 82 |
*
Genotype 1 and genotype 4 patients combined. ACTG AIDS Clinical Trial Group;
APRICOT AIDS Pegasys Ribavirin International Co-infection Trial;
ANRS Agence nationale de recherches sur le sida